Advancing the Next Generation of
Mental Health Therapeutics

PsyRx is a CNS pharmaceutical development company advancing innovative ibogaine-based therapies for depression, PTSD, and other neuropsychiatric disorders.
Our Science
PsyRx is developing a novel ibogaine-based therapeutic approach designed to enhance neuroplasticity and improve outcomes for patients with depression and related neuropsychiatric disorders.
Once-daily oral dosage form
Administered without clinical supervision
Designed for efficacy with minimal side effects
No interruption to patients' daily lives

Transforming Mental Health Treatment

PsyRx is pursuing a differentiated pharmaceutical development strategy based on low-dose ibogaine, designed to explore therapeutic benefits while supporting safety, tolerability, and scalability within a regulated pharmaceutical framework.
Founded in 2019, PsyRx is focused on developing differentiated therapies for major unmet needs in mental health. Unlike clinic-based psychedelic treatment models, PsyRx is pursuing a pharmaceutical pathway designed to create scalable, prescription-based therapeutic products.
Learn More

Unleashing the Therapeutic
potential of Ibogaine

A Unique Approach to Neuropsychiatric Disorders

Ibogaine is a naturally derived compound with a unique pharmacological profile that has attracted increasing scientific interest for its potential role in addressing neurological and psychiatric disorders. Derived from the root bark of the iboga tree (Tabernanthe iboga), native to Central and West Africa, ibogaine was historically marketed in France until the 1970s as a stimulant under the name Lambarène.

Unlike conventional antidepressants that primarily target a single biological pathway, ibogaine has been shown to interact with multiple neurobiological systems involved in mood regulation, neural adaptation, and neuroplasticity. Research suggests these mechanisms may contribute to improved therapeutic outcomes and a potentially faster clinical response.

A Differentiated Development Strategy

PsyRx is pursuing a differentiated pharmaceutical development strategy based on low-dose ibogaine, designed to explore therapeutic benefits while supporting safety, tolerability, and scalability within a regulated pharmaceutical framework.

The Company’s development approach focuses on transforming promising scientific observations into pharmaceutical-grade products supported by rigorous preclinical research, regulatory planning, and clinical validation — creating innovative treatment options for patients suffering from depression, PTSD, and related neuropsychiatric disorders.

Key Objectives

Faster therapeutic onset
Improved response in difficult-to-treat patient populations
Reduced side-effect burden
Improved patient adherence
Supplying GMP-standard active pharmaceutical ingredients (APIs) of ibogaine and psilocybin to pharmaceutical and biotechnology companies
Clinical advantage: faster onset of action, improved mood outcomes, and a reduced side-effect profile, supporting lower patient burden and treatment cost
Incorporating microdoses of ibogaine or psilocybin into existing psychiatric medications
Regulatory advantage: a development pathway designed to support an accelerated regulatory approval process
Learn More

Natural Pharmaceutical-Grade
Psilocybin, in Four Steps

1
Preparation of Master
Cell Bank
We begin by selecting the highest-performing psilocybin mushroom strains and preparing a master cell bank to ensure a consistent manufacturing process, both today and at future scale.
2
Mycelium Isolation
To manufacture a natural psilocybin API batch, we grow specific mycelium from the master bank in a controlled bioreactor for two weeks.
3
Extraction and Isolation
(GMP Process)
We extract the mushroom metabolites to obtain a full-spectrum extract, followed by isolation of greater than 99% pure natural psilocybin.
4
Packaging and Delivery
(GMP Process)
The final product is packaged and stored in a controlled environment in accordance with stability testing validations and requirements, until delivery to our customers.

Science & Technology

Depression and trauma-related disorders remain among the most significant public health challenges globally. Although current antidepressants have helped millions of patients, many continue to experience delayed onset of action, partial treatment response, treatment resistance, relapse, and side effects limiting adherence.

PsyRx is investigating novel ibogaine-based therapeutic approaches that may influence neuroplasticity, neural adaptation, and mood-related biological pathways. Our programs are developed according to internationally recognized pharmaceutical standards, including GMP manufacturing, regulatory compliance, controlled clinical studies, and quality-by-design principles. Platform characteristics

Leveraging existing know-how and technology

Controlled, GMP-aligned processes
Reproducible quality and yield
Scalable manufacturing suitable for late-stage development
Cost-efficient production design

Management

Itay Hecht
Business Development
Itay is an entrepreneur with vast experience in the private and public sectors. He oversaw the first IPO of medical Cannabis company in the Tel Aviv Stock Exchange. Prior to PsyRx Itay served as the CEO of Hi-Pharma Ltd, a medical cannabis company for 2 years and 7 years as COO of Palgi Sharon - Israeli Municipal Water Corporation.
Moshe Neuman, PhD
Regulatory Affairs
Over 27 years of experience in leading regulatory affairs consulting providing professional expert advice and integrated CRO services to Israeli startup companies at early-stage development, in the fields of pharmaceutical, biotechnology, medical devices.
Asher Holtzer, PhD
Co-founder, Board Member
Over 30 years' management experience in the medical device and biotech industry. Founded several successful bio-tech companies, including InspireMD (NYSE MKT: NSPR), UroGen Pharma (NASDAQ: URGN), part of the management team of Biosense – acquired by Johnson & Johnson in 1997.
Kobi Buxdorf, PhD
Co-founder, Board Member
Entrepreneur, founder of Cannador and Tincoli, Co founder of Wilk (TLV:WILK). Over 10 years of academic and industrial research and managing experience, in microbiology, molecular biology, plant sciences, diagnostics and medical devices. Extended background in regulation, business development and commercialization of basic science.
Prof. Moshe Kotler MD, M.HA
Medical Director
Professor emeritus of psychiatry at the Tel Aviv University School of Medicine. Served as the Deputy Dean (for medical education) of the Faculty of Medicine. Former Director of Be'er Ya'akov Mental Health Medical Center – Ness Ziona.

Board of Directors

Itamar Grotto
Executive Chairman
Asher Holtzer
CCO & Co Founder
Kobi Buxdorf
CTO & Co Founder
Itay Hecht
CEO & Co Founder

Partner With
PsyRx

PsyRx welcomes discussions with pharmaceutical companies, academic institutions, clinical investigators, strategic investors, veterans organizations, and government funding agencies.
Get In Touch





    Skip to content